To hear about similar clinical trials, please enter your email below
Trial Title:
Efficacy of Memantine in Prevention of Oxaliplatin-induced Peripheral Neurotoxicity
NCT ID:
NCT05834231
Condition:
Cancer
Conditions: Official terms:
Neurotoxicity Syndromes
Memantine
Study type:
Interventional
Study phase:
Phase 1/Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Prevention
Masking:
Double (Participant, Outcomes Assessor)
Intervention:
Intervention type:
Drug
Intervention name:
Memantine
Description:
oral
Arm group label:
Intervention
Intervention type:
Drug
Intervention name:
Placebo
Description:
oral
Arm group label:
Control
Summary:
Memantine is a drug for the management of Alzheimer's Disease (AD) due to its promising
neuroprotective properties. We hypothesize that Memantine possesses a beneficial role
against chemotherapy-induced neuronal damages.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
histologically confirmed diagnosis of stage III colorectal cancer performance status < 2
according to Eastern Cooperative Oncology Group (ECOG) score adequate renal function
(glomerular filtration rate ≥ 90)
Exclusion Criteria:
preexisting neuropathic or brain disorders, a previous use of chemotherapeutic agents
including oxaliplatin use of drugs reported to have neuroprotective role
Gender:
All
Minimum age:
18 Years
Maximum age:
75 Years
Healthy volunteers:
No
Start date:
August 2023
Completion date:
October 2024
Lead sponsor:
Agency:
Mansoura University
Agency class:
Other
Source:
Mansoura University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05834231
